Phenoxyacetic acids as PPARδ partial agonists: Synthesis, optimization, and in vivo efficacy

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 8, 2011, Pages 2345-2350

  Evans, Karen A ^a   Shearer, Barry G ^a   Wisnoski, David D ^a   Shi, Dongchuan ^a   Sparks, Steven M ^a   Sternbach, Daniel D ^a   Winegar, Deborah A ^a   Billin, Andrew N ^a   Britt, Christy ^a   Way, James M ^a   Epperly, Andrea H ^a   Leesnitzer, Lisa M ^a   Merrihew, Raymond V ^a   Xu, Robert X ^a   Lambert, Millard H ^a   Jin, Jian ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Partial agonist; PPARd

Indexed keywords

PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PHENOXYACETIC ACID DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CRYSTAL STRUCTURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VIVO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ACETIC ACIDS; ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MALE; MICE; MICROSOMES, LIVER; PPAR DELTA; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953278556     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.077     Document Type: Article

References (23)

1. J. Berger, and D.E. Moller Annu. Rev. Med. 3 2002 409
2. S.M. Reilly, and C.-H. Lee FEBS Lett. 582 2008 26
3. W.R. Oliver Jr., J.L. Shenk, M.R. Snaith, C.S. Russell, K.D. Plunket, N.L. Bodkin, M.C. Lewis, D.A. Winegar, M.L. Sznaidman, M.H. Lambert, H.E. Xu, D.D. Sternbach, S.A. Kliewer, B.C. Hansen, and T.M. Willson Proc. Natl. Acad. Sci. U.S.A. 98 2001 5306
4. D.L. Sprecher, C. Massien, G. Pearce, A.N. Billin, I. Perlstein, T.M. Willson, D.G. Hassall, N. Ancellin, S.D. Patterson, D.C. Lobe, and T.G. Johnson Arterioscler. Thromb. Vasc. Biol. 27 2007 359
5. M.L. Sznaidman, C.D. Haffner, P.R. Maloney, A. Fivush, E. Chao, D. Goreham, M.L. Sierra, C. LeGrumelec, H.E. Xu, V.G. Montana, M.H. Lambert, T.M. Willson, W.R. Oliver Jr., and D.D. Sternbach Bioorg. Med. Chem. Lett. 13 2003 1517
6. Examples of PPARδ partial agonist ligands: B.G. Shearer, H.S. Patel, A.N. Billin, J.M. Way, D.A. Winegar, M.H. Lambert, R.X. Xu, L.M. Leesnitzer, R.V. Merrihew, S. Huet, and T.M. Willson Bioorg. Med. Chem. Lett. 18 2008 5018
7. P. Sauerberg, G.S. Olsen, L. Jeppesen, J.P. Mogensen, I. Pettersson, C.B. Jeppesen, J.R. Daugaard, E.D. Galsgaard, L. Ynddal, J. Fleckner, V. Panajotova, Z. Polivka, P. Pihera, M. Havranek, and E.M. Wulff J. Med. Chem. 50 2007 1495
8. Examples of the phenoxyacetic acid template have also been established by others as full agonist ligands for PPARδ, for example: C.A. Luckhurst, M. Ratcliffe, L. Stein, M. Furber, S. Botterell, D. Laughton, W. Tomlinson, R. Weaver, K. Chohan, and A. Walding Bioorg. Med. Chem. Lett. 21 2011 531
9. C.A. Luckhurst, L.A. Stein, M. Furber, N. Webb, M.J. Ratcliffe, G. Allenby, S. Botterell, W. Tomlinson, B. Martin, and A. Walding Bioorg. Med. Chem. Lett. 21 2011 492
10. R.V. Connors, Z. Wang, M. Harrison, A. Zhang, M. Wanska, S. Hiscock, B. Fox, M. Dore, M. Labelle, A. Sudom, S. Johnstone, J. Liu, N.P.C. Walker, A. Chai, K. Siegler, Y. Li, and P. Coward Bioorg. Med. Chem., Lett. 19 2009 3550
11. R. Zhang, A. Wang, A. DeAngelis, P. Pelton, J. Xu, P. Zhu, L. Zhou, K. Demarest, W.V. Murray, and G.-H. Kuo Bioorg. Med. Chem. Lett. 17 2007 3855
12. M.D. Leibowitz, C. Fievet, N. Hennuyer, J. Peinado-Onsurbe, H. Duez, J. Berger, C.A. Cullinan, C.P. Sparrow, J. Baffic, G.D. Berger, C. Santini, R.W. Marquis, R.L. Tolman, R.G. Smith, D.E. Moller, and J. Auwerx FEBS Lett. 473 2000 333
13. 3 buffer 0.5/99.5 pH 10.
14. P.J. Brown, T.A. Smith-Oliver, P.S. Charifson, N.C.O. Tomkinson, A.M. Fivush, D.D. Sternbach, L.E. Wade, L. Orband-Miller, D.J. Parks, S.G. Blanchard, S.A. Kliewer, J.M. Lehmann, and T.M. Willson Chem. Biol. 4 1997 909
15. B.R. Henke, S.G. Blanchard, M.F. Brackeen, K.K. Brown, J.E. Cobb, J.L. Collins, W.W. Harrington Jr., M.A. Hashim, E.A. Hull-Ryde, I. Kaldor, S.A. Kliewer, D.H. Lake, L.M. Leesnitzer, J.M. Lehmann, J.M. Lenhard, L.A. Orband-Miller, J.F. Miller, R.A. Mook Jr., S.A. Noble Jr., W. Oliver, D.J. Parks, K.D. Plunket, J.R. Szewczyk, and T.M. Willson J. Med. Chem. 41 1998 5020
16. H.E. Xu, M.H. Lambert, V.G. Montana, K.D. Plunket, L.B. Moore, J.L. Collins, J.A. Oplinger, S.A. Kliewer, R.T. Gampe, D.D. McKee, J.T. Moore, and T.M. Willson Proc. Natl. Acad. Sci. U.S.A. 98 2001 13919 and references cited therein
17. I. Pettersson, S. Ebdrup, M. Havranek, P. Pihera, M. Korinek, J.P. Mogensen, C.B. Jeppesen, E. Johansson, and P. Asuerberg Bioorg. Med. Chem. Lett. 17 2007 4625
18. 2, 140 bar, 40 °C, 2 mL/min on an AS column monitored at 215 nm. (S)-3a, 95% ee, 87% pure and (R)-3b, 98% ee, 93% pure.
19. free = 23.6%, PDB code 3PEQ.
20. Distances reported are the average distances from the residues in the crystal structure of 48 bound to PPARd which has two subunits. Compounds 3a and 3b were overlaid into both subunits, with the (S)-methyl of 3a lying 2.01 and 2.26 from Thr289 in the two subunits, and with the (R)-methyl of 3b lying 2.78 and 2.93 from Leu469 in the two subunits.
21. B.G. Shearer, D.J. Steger, J.M. Way, T.B. Stanley, D.C. Lobe, D.A. Grillot, M.A. Iannone, M.A. Lazar, T.M. Willson, and A.N. Billin Mol. Endocrinol. 22 2008 523
22. All animal studies were conducted after review by the GSK Institutional Animal Care and Use Committee and in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals.
23. ob/ob mice, 6 weeks of age. Positive control: GW610742X (30 mg/kg). Vehicle: HPMC/Tween. Compound dosed orally (10, 30, 100 mg/kg) once daily for 15 days. OGTT performed on fasted animals at day 12 of dosing.